Related Experiment Video
Updated: May 7, 2026
Isolation and Physiological Analysis of Mouse Cardiomyocytes
Published on: September 7, 2014
Dusp14-Mediated Dephosphorylation of MLKL Protects Against Cardiomyocyte Necroptosis in Hypothyroidism-Induced Heart
Yitian Zheng1,2, Yueyue Cao1,2, Wenyao Wang1,2
1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China (Y. Zheng, Y.C., W.W., Y.T., C.L., M.Z., Y.S., Y.-g.-s.W., J.Q., C.W., J.Y., J. Zheng, J.G., J.W., Y. Zhang, H.X., Y.-Y.Z., Y.-D.T.).
Insights
Dual specificity phosphatase 14 (Dusp14) protects the heart from hypothyroidism-induced failure by inhibiting necroptosis. A novel compound, P077-0472, activates Dusp14, offering a potential therapeutic strategy for heart conditions linked to thyroid dysfunction.
Area of Science:
- Cardiovascular Biology
- Molecular Pathology
- Endocrinology
Background:
- Hypothyroidism causes multi-organ dysfunction, particularly affecting the heart and leading to heart failure.
- The precise mechanisms underlying hypothyroidism-induced heart failure are not fully understood.
- Thyroid hormone replacement can improve heart function but may increase arrhythmia risk, highlighting the need for targeted therapies.
Purpose of the Study:
- To investigate the role of dual specificity phosphatase 14 (Dusp14) in hypothyroidism-induced heart failure.
- To elucidate the involvement of necroptosis in the pathogenesis of this condition.
- To identify potential therapeutic compounds for managing hypothyroidism-related heart failure.
Main Methods:
- A mouse model of hypothyroidism-induced heart failure was created using propylthiouracil.
- Dusp14 knockout mice and Dusp14-overexpressing mice were utilized.
- Adeno-associated virus-mediated gene delivery and cellular experiments were performed.
- Molecular docking was employed to identify small molecule compounds targeting Dusp14.
Main Results:
- Hypothyroidism activated myocardial necroptosis, evidenced by elevated lactate dehydrogenase and phosphorylated MLKL levels.
- Myocardial-specific Dusp14 overexpression attenuated necroptosis and improved cardiac function in hypothyroid mice.
- Dusp14 knockout worsened cardiac dysfunction and necroptosis.
- A novel compound, P077-0472, was identified as a Dusp14 activator that inhibits cardiomyocyte necroptosis.
Conclusions:
- Dusp14 plays a protective role by inhibiting cardiomyocyte necroptosis in hypothyroidism-induced heart failure.
- The small molecule compound P077-0472 demonstrates potential as a therapeutic agent by activating Dusp14.
- Targeting Dusp14-mediated necroptosis offers a promising strategy for treating heart failure in hypothyroid patients.
Background:
Hypothyroidism leads to multiple organ dysfunction, with the heart the most affected. However, the pathologic mechanism of hypothyroidism-induced heart failure remains to be completely elucidated. Thyroid hormone replacement therapy enhances myocardium systolic function but increases the occurrence of arrythmias. There is an urgent need to explore these mechanisms in detail and to discover and develop drugs that can target and manage heart failure in patients with hypothyroidism.
Methods:
In this study, a mouse model of hypothyroidism-induced heart failure was established through the administration of propylthiouracil. Dusp14 knockout mice were generated, and adeno-associated virus-mediated cardiomyocyte-specific overexpression of Dusp14 (dual specificity phosphatase 14) was used in combination with related cellular experiments to investigate the protective effects of Dusp14 on hypothyroidism-induced heart failure. Further analyses confirmed the crucial involvement of necroptosis in the pathogenesis of hypothyroidism-induced heart failure, and demonstrated the protective role of Dusp14 in modulating necroptosis. In addition, a novel small molecule compound that effectively regulates Dusp14 activity in vitro was identified through molecular docking, providing a potential therapeutic avenue.
Results:
Dusp14 regulates necroptosis and mitigates hypothyroidism-induced heart failure. Myocardial tissue sections from mice in the hypothyroidism group showed positive Evans blue dye staining, and the serum levels of the myocardial injury marker lactate dehydrogenase were significantly higher compared with the euthyroid group (n=8). In addition, phosphorylation levels of the necroptosis marker MLKL (mixed lineage kinase domain-like protein) were significantly elevated, indicating the activation of necroptosis (n=8). These findings suggest that myocardial necroptosis is activated during hypothyroidism. Myocardial-specific overexpression of Dusp14 reduced myocardial necroptosis and improved myocardial contractile function in hypothyroid mice (n=8). In contrast, Dusp14 knockout exacerbated myocardial contractile dysfunction and necroptosis in these mice (n=5-7). These results indicate that Dusp14 alleviates hypothyroidism-induced heart failure by inhibiting necroptosis. P077-0472, a small molecule compound, was identified as an activator of Dusp14, which could inhibit cardiomyocyte necroptosis from hypothyroidism (n=6).
Conclusions:
Dusp14 inhibits cardiomyocyte necroptosis from hypothyroidism and consequently rescues damaged cardiomyocytes. P077-0472, a novel small molecule compound that activates the dephosphorylation function of Dusp14, could inhibit cardiomyocyte necroptosis from hypothyroidism.
More Related Videos
06:51Isolation and Culture of Adult Mouse Cardiomyocytes for Cell Signaling and in vitro Cardiac Hypertrophy
Published on: May 21, 2014
11:00Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy